Retinal Prosthesis

Subcategory of brain-computer-interface. Implantable devices that substitute for lost photoreceptors by converting light (or camera data) into electrical stimulation of surviving retinal neurons — the retina being an extension of the brain. See retinal-prosthesis-companies for the company schema.

How it works

For a patient with lost photoreceptors (rod-cone dystrophies, geographic atrophy from AMD) but an otherwise intact inner retina, two target cell types exist:

• Bipolar cells (first synapse past photoreceptors): simpler, bitmapped-like encoding; accessed with a subretinal device.¹
• Retinal ganglion cells (RGCs): output layer forming the optic nerve; complex encoding; targetable by AAV gene therapy/optogenetics.

Electricity is delivered via electrodes: epiretinal (on the retinal surface, e.g. Argus II), subretinal (under the retina, e.g. PRIMA, Alpha AMS), or suprachoroidal (between choroid and sclera, e.g. BVT). A camera/glasses system provides power and data; PRIMA is fully photovoltaic — near-infrared light projected by glasses powers a 2 × 2 mm chip with 378 pixels that acts like a miniature solar panel, exciting bipolar cells.²

Because most emerging approaches are light-driven (photovoltaic chips, photoacoustic films, nanomaterial prostheses), evaluating them in behaving animals depends on precisely patterned retinal illumination — delivered with DMD-based (digital micromirror device) projection systems, such as the head-mounted projector for freely-moving rats that presents 525-nm patterns to the healthy retina or 915-nm patterns to a photovoltaic implant.³ The projection toolchain is covered in augmented-vision. The clinical case is the PRIMA glasses, whose projector is a pulse-width-modulated micromirror (DMD) engine projecting 880-nm patterns onto the photovoltaic chip (US12061332 — see the PRIMAvera section).

Indications & patient populations

• Geographic atrophy (GA) due to AMD — >5 million people worldwide; progressive photoreceptor destruction at the macula; PRIMA’s current target.⁴
• Retinitis pigmentosa (RP) — ~2 million people; inherited; the historical target of Argus II, Alpha AMS, BVT, Nano Retina.
• Stargardt disease — next target for PRIMA expansion; also investigational.

Landmark clinical evidence

PRIMAvera (PRIMA, NEJM 2026) — pivotal trial

The PRIMAvera study (NCT04676854; Holz et al., NEJM 2026;394:232–242) is the largest randomised-controlled-level evidence for a retinal prosthesis to date, and the first demonstration of form vision (recognisable letters/words) rather than mere phosphene perception.

Study design: Open-label, multicenter, prospective, single-arm, baseline-controlled confirmatory trial. 38 participants with GA due to AMD, VA ≥ logMAR 1.2 (≤20/320), across 17 sites in 5 European countries. Primary endpoint: proportion with ≥0.2 logMAR (≥10 ETDRS letter) VA improvement at 12 months.

Device: 2 × 2 mm, 30 µm thick crystalline silicon implant; 378 photovoltaic pixels (100 µm each); NIR glasses (880 nm, 30 Hz, 3.5 mW/mm²); zoom 1×–12×. Stimulates bipolar cells (not RGCs), preserving inner retinal processing. No transcutaneous wires (photovoltaic). Its 30-µm thickness is itself NIR-driven design: 905-nm light penetrates only ~35 µm into silicon, so the array is thinned to just absorb the illumination pulse.⁵

The glasses (projection system). Camera → pocket processor → NIR pattern projected onto the implant. The projector is a DMD-based engine at 880 nm — the pulsed beam is divided by a micromirror array with individual pulse-width modulation per mirror, synchronised with the light source and duty-cycle-limited for ocular/implant safety (Pixium projector patent US12061332; the Stanford preclinical rigs used the same architecture — an 880-nm laser + DLP “Light Commander” DMD + slit-lamp optics).⁶ Nominal operation: 30 Hz (flicker fusion) with percept brightness via 0.7–9.8 ms pulses at 3.5 mW/mm² peak. First-generation glasses were opaque (VR; PRIMA-1: 17.5° field, ~10.5 µm resolution); since October 2019 patients use transparent AR glasses (PRIMA-2: 18.5° field, 6.7 µm resolution, projection adapted to the patient’s refraction), enabling simultaneous central prosthetic and peripheral natural vision, with electronic zoom (up to ×12) and an optional tinted lens (~65% white-light attenuation) for bright environments.^{7 8}

Efficacy at 12 months:

Measure	Result
Primary: ≥0.2 logMAR improvement (observed, 26/32)	81.3% (95% CI 63.6–92.8%; p<0.001)
Primary: ≥0.2 logMAR (multiple imputation, all 38)	79.9% (95% CI 65.6–94.2%; p<0.001)
≥0.3 logMAR improvement (post-hoc, 25/32)	78.1%
Mean VA improvement with PRIMA glasses	logMAR 0.49 (~24.5 ETDRS letters)
Mean VA improvement, participant’s choice	logMAR 0.51 (~25.5 letters, 5 lines)
Best individual improvement	logMAR 1.18 (59 letters)
Prosthetic VA (direct stimulation, no camera)	logMAR 1.32 ± 0.16 (20/417) = theoretical pixel limit
Natural peripheral VA change (no glasses)	0.00 logMAR — no deterioration
Home use: read letters/numbers/words	84.4% (27/32)
User satisfaction (medium-to-high)	68%

Note: reading zoom-enhanced fonts down to 20/42 was reported — far exceeding the raw pixel resolution limit (equivalent to ~20/400) due to digital zoom + eye movement super-resolution.

Safety (26 SAEs in 19/38 participants): Most common: ocular hypertension (6 events), peripheral retinal break (5), macular hole (3), subretinal haemorrhage (4 events in 3 participants). 21/26 SAEs (81%) occurred within 2 months; 20/21 resolved within 2 months. 22/26 mild-to-moderate; 4 severe (macular hole, ocular hypertension, retinal detachment, PVR — three in one participant). No SAE was device-alone (all procedure-related or procedure+device). CNV in 2 participants (5.2%), treated with anti-VEGF. DSMB conclusion: benefits outweigh risks.

Comparisons with prior devices:

Device	Placement	Best acuity reported
Argus II (Second Sight)	Epiretinal	logMAR 1.8 (20/1260)
Alpha AMS (Retina Implant AG)	Subretinal	~20/546
BVT 44-ch (Bionic Vision Technologies)	Suprachoroidal	logMAR ~3.0
PRIMA (Science Corp.)	Subretinal	logMAR 1.32 native; reading to 20/42 with zoom

Longevity: 4-year feasibility study (5 patients) showed stable anatomy, minimal inner retinal thinning, mean VA logMAR 0.64 (32 letters) at 48 months.

Upgrade pathway: Wireless design enables in-situ replacement with higher-resolution next-generation chips (Bhuckory et al., Nat Commun, 2025; DOI: 10.1038/s41467-025-58084-y) or tiling multiple 2 × 2 mm modules to cover larger atrophic areas.⁹

• Argus II (epiretinal, 60 channels) — CE 2011, FDA 2013 (first FDA-approved); restored light perception/object localization; discontinued 2019, patients left unsupported. Shows that approval ≠ sustainable product.

  The Argus II abandonment (IEEE Spectrum, Feb 2022): Second Sight sold the Argus II for ~$150,000(totalcostwithsurgeryandrehabestimatedat$497,000), but was losing money on every unit. On 18 Jul 2019, the company told patients it was phasing out the retinal implant to focus on the Orion cortical implant, promising continued support — but internally “didn’t really support the basic Argus after that.” In Mar 2020, Second Sight laid off most employees, announced “intention to wind down operations,” and sold off physical assets at auction — without informing patients. Over 350 implantees worldwide were left without support: Barbara Campbell’s implant failed in a subway station and never worked again; Ross Doerr couldn’t get an MRI because Second Sight wasn’t answering the phone; Jeroen Perk’s VPU shattered when dropped and he had to crowdsource spare parts from other patients. The FDA postapproval study (30 patients, 2007–2019) recorded 36 serious adverse events; Spectrum’s analysis of 90 MAUDE reports (2014–2020) found ~80% required surgical intervention, including detached retinas in ~15% of cases. A researcher who found “weakness” in the device’s vision quality says Second Sight blocked publication. In Feb 2022, Second Sight announced a merger with Nano Precision Medical; NPM’s CEO called the past “simply not relevant to the new future.” Daniel Palanker (Stanford, PRIMA inventor): “If you provide excellent vision, there will be lots of patients. If you provide crappy vision, there will be very few.” ¹⁰

• Alpha AMS (subretinal, 1,500 electrodes) — CE 2013; company dissolved 2019.

• BVT suprachoroidal (44-ch) — phase I (3 patients) + phase II (4 patients); stable up to 10 years; improvements in mobility/ADL; FDA Breakthrough Device designation; no commercial approval yet.¹¹

Regulatory timeline (PRIMA)

• 2017 first-in-human (France; Pixium Vision); 2018 FDA IDE; 2020 first US implant (UPMC).
• 2023 FDA Breakthrough Device designation; Jan 2024 Pixium liquidation → Apr 2024 assets to science-corp; Oct 2025 NEJM results; Jul 2026 **CE mark (MDR, DEKRA)
  • EU commercial launch**, first commercial implant expected in Germany; two FDA HUD designations (July 2026), FDA review ongoing.

Market estimates (commercial forecast, 2026)

A Spherical Insights & Consulting market note (Aug 2026) projects the global artificial retinal implants market growing from USD 420 million (2025) to USD 972 million (2035) — a CAGR of 8.75% over 2026–2035 — with North America at ≈47% of 2025 revenue and Asia-Pacific the fastest-growing region (China, India, Japan, and South Korea named as drivers); North America is expected to remain the largest revenue pool on reimbursement, clinical-trial infrastructure, and specialist centres. Its company list names Second Sight, Science Corporation, Pixium Vision, Nano Retina, Retina Implant AG, BVT, LambdaVision, iBIONICS and others (several entries — Optobionics, Medtronic, Abbott — are legacy or tangential players, so only the leading group reflects current market participants).¹²

Caveats — vendor estimate, not clinical evidence: Spherical Insights is a commercial market-research firm, and the note carries template artifacts: its statistics list prints “CAGR of 75%” (a decimal error — the headline and body both say 8.75%), and its segmentation paragraph describes reagent-market categories (“Liquid Reagents, Dry Reagents… Blood, Tissue, Cells”), evidently copied from an unrelated template. Treat the absolute figures as directional only — an order-of-magnitude frame alongside device economics such as Argus II’s ~$150kprice($497k with surgery and rehab) and PRIMA’s CE mark + EU launch.

Photoacoustic retinal prosthesis (emerging modality)

A fourth modality, distinct from electrical, photovoltaic, and cell-based approaches, was demonstrated in 2026 by Leong et al. (Nat Commun 17, 815):

Mechanism: A flexible PDMS/candle-soot/PDMS film, implanted subretinally, converts 1030-nm pulsed NIR laser pulses into localised ultrasound waves via the photoacoustic effect. These waves stimulate mechanosensitive retinal cells (bipolar cells, photoreceptors when present, and other inner retinal neurons upstream of RGCs) — cells that persist even after photoreceptor degeneration in AMD or RP.¹³

Key performance figures (pre-clinical, rat):

Parameter	Value
Lateral acoustic resolution	51 µm FWHM (50-µm laser fibre)
Film thickness (thick/thin)	115 µm (PDMS/CS/PDMS) / 40 µm (PDMS-CNT)
Peak-to-peak pressure	146.2 kPa at 0.9 mm; ~0.05 MPa threshold for SC activation
Temperature rise at film surface	<0.52 °C — within FDA ophthalmic US guidelines
MI / ISPTA	<0.03 / <0.06 mW/cm² (PDMS/CS/PDMS); <0.1 / <0.9 mW/cm² (CNT)
RGC modulation (WT ex vivo)	78% of RGCs within 300 µm (74% of sites)
RGC modulation (P23H degenerated ex vivo)	39% of RGCs
In vivo (rat): cSC activation	25–38% of full-field white-light-activated area

How it compares to PRIMA (photovoltaic): PRIMA achieves 20/460–20/565 in patients at 100 µm pixel pitch; the PA film demonstrates 51-µm acoustic resolution and in principle supports the full 25 mm² macular coverage area (vs. PRIMA’s 2×2 mm chip, 7° field) because the flexible film can be tiled continuously and the pixel pattern is defined optically by laser scanning. Target pixel density: 2,500 px/mm². However, PRIMA is CE-marked and in clinical use; the PA approach is pre-clinical only in 2026.

Mechanosensitivity circuit: Pharmacological dissection showed photoreceptors generate most short-latency (<45 ms) RGC responses to ultrasound (L-AP4 abolished them); inner retinal cells also contribute. Glutamate neurotransmission is required to relay the mechanosensitive signal to RGCs. Likely candidate channels: Piezo1/2 (expressed in RGCs and RPE), TRPV1/2/4.

Commercial translation: BU patents licensed to axorus (Paris, France), which is developing a contact-lens form factor. Chen Yang also planning a US start-up. Next stage: first-in-human safety study.¹⁴

Tellurium nanowire nanoprosthesis (emerging modality)

A second non-electrode modality arrived in 2025 with Wang et al. (Science 388: eadu2987): a subretinal nanoprosthesis of tellurium nanowire networks (TeNWNs) that converts broadband light — visible through near-infrared II (NIR-II, up to 1,550 nm) — into electrical signals at zero electrical bias, requiring neither an implanted power supply nor extraocular goggles (contrast PRIMA’s projected 880-nm NIR illumination).¹⁵

Mechanism: randomly oriented Te nanowires form a porous, interconnected film (~150 nm thick) implanted in the subretinal space in place of degenerated photoreceptors, contacting bipolar cells and RGCs. Tellurium’s narrow bandgap (0.3 eV) plus engineered asymmetry — Sn substitutional defects and Te vacancies that break the helical lattice’s centrosymmetry, and nanowire–retina heterointerfaces — produces spontaneous photocurrents across the full visible-to-NIR-II range; the porous network also minimizes mechanical stress on the retina.¹⁶ The film’s spatial photoresponse was characterised pre-implantation on a platform combining a multielectrode array, a digital micromirror device (DMD) and a 635-nm laser, mapping voltage responses to projected patterns across a 1,200 × 1,200 μm area.¹⁷

Key results (pre-clinical):

Model	Result
Blind mice (Pde6brd1/rd1/cDTA; complete photoreceptor loss)	Pupillary light reflex restored (635-nm visible and 1,550-nm NIR-II; untreated blind mice show no IR reflex); visually cued learning (water-reward and choice-box tasks) under both spectra; RGC activation thresholds as low as 18.98 mW mm⁻² (NIR-II); response latency 200–600 ms and tuning up to 5 Hz mirroring photoreceptor signalling; cortical VEPs confirm propagation — all at intensities ~80× below the clinical safety threshold
Macaca fascicularis	Subretinal integration stable for 112 days (fundus + OCT; no detachment or inflammation); robust retina-derived responses to visible and infrared light; flash ERGs to 940-nm NIR-I light showed a- and b-wave responses (b-wave = bipolar-cell origin) significantly larger than in unimplanted controls; infrared vision gained without impairing normal vision

Positioning and caveats: the paper reports record-high photocurrents and the widest responsive spectrum among photosensitivity-restoration approaches (visible–NIR-II), with the companion Perspective emphasising a two-fold promise: restoring lost sensitivity and extending perception beyond the rods-and-cones spectrum.¹⁸ It remains animal-stage (mice + macaques), with the open-access commentary flagging the blockers: mouse receptive fields (135.57 deg² vs 163.02 deg² for normal RGCs) limit spatial discrimination, stability is demonstrated only to 112 days (macaque), and TeNWN degradation/glial scarring and spectral isolation (for colour vision) are unaddressed.¹⁶ In the landscape it forms a third subretinal energy-transduction strategy alongside the gated photovoltaic pixel array (PRIMA; clinical) and the photoacoustic film (above; pre-clinical).

Resolution limits and the patent landscape (2026)

According to a PatSnap Eureka AI-generated patent landscape analysis (2026), the field divides across three patent sub-domains:¹⁹

Sub-domain	Mechanism	Best acuity (patent dataset)	Key assignees
Electronic electrostimulation	Microelectrode array (epi- or subretinal), camera, wireless encoding	~20/1400	Cornell Univ. (EP 2022, CN 2013), Second Sight (AU 2005), STMicro (IT 2012), I-Lumen Scientific (KR 2023)
Photovoltaic subretinal	Photodiode array, NIR headset, no transcutaneous wires	20/460–20/565 (PRIMA)	Stanford Univ. (CN 2023), Alan Y. Chow (DE 2005)
Cell-based RPE	hESC/iPSC-derived RPE transplant to restore photoreceptor support	Pre-clinical	Astellas (TW 2023), Lineage Cell Therapeutics (AU/US/WO/BR/JP), NIH/HHS (CN 2024)

The central barrier across all three modalities is spatial resolution: current electrodes are 50–450 µm in diameter; individual neurons are much smaller. The electrode-to-cell size mismatch has been explicitly identified in the Cornell EP patent as the limiting constraint. Even the best photovoltaic systems (PRIMA) achieve 20/460 — still below the 20/200 legal blindness threshold. Stanford’s 2023 CN filing targets 20/100 or better via a 25 µm pixel pitch with optical field confinement (pre-charging architecture where pixels going dark act as transient local return electrodes, reducing inter-electrode crosstalk).

Five emerging patent directions (2023–2026)

1. Optical field confinement — Stanford CN 2023: pre-charging pixels, 25 µm pitch, targets 20/100+.
2. Scaffold-engineered RPE patches — NIH CN 2024: PLGA scaffold (20–30 µm thick, ~1:1 DL-lactide/glycolide, <1 µm pore size, 150–650 nm fibers) for polarized RPE cell delivery; a shift from suspension injection to structured tissue replacement.
3. AI-enabled remote OCT monitoring — Notal Vision (US 2023, 2025): daily home OCT + algorithmic intervention scheduling. Also Novartis (US 2026), Roche (US 2022), EPFL (JP 2025). Growing “IP thicket” around post-implant monitoring.
4. Bidirectional stimulation + spectroscopy — Diamentis Inc. (BR 2024): simultaneous light stimulation and spectral response recording; enables real-time closed-loop calibration.
5. Gene therapy convergence — Octant Inc. (WO 2025) and Nightstarx Ltd. (SG 2021): gene therapy for RP positioned as a complement to prosthetics, not a competitor — preserves residual photoreceptors in partially-degenerated retinas while prosthetics serve fully-lost cases.

IP geography: Active photovoltaic device hardware filings are concentrated in CN (Stanford) and legacy DE (Chow) — US, EP, JP, and KR are identified as white spaces for next-generation photovoltaic architectures. Cell-based approaches show the broadest multi-jurisdictional prosecution (TW, AU, US, WO, CN, JP). Diagnostic/AI monitoring has the most distributed assignee base (6 organisations). The Cornell EP patent notably extends the retinal neural-encoding architecture to robotic/machine vision devices, which creates potential licensing relevance for neuromorphic computing.¹⁹

Open questions

• Which diseases can benefit (GA/AMD now; RP/Stargardt next; wet AMD excluded)?
• Resolution ceiling: pixel miniaturisation below 25 µm and crosstalk suppression are primary pathways to clinically meaningful acuity. Can photovoltaic (Stanford 25 µm pitch) or electronic (Cornell single-cell encoder) approaches reach 20/200?
• Cell-based RPE vs. photovoltaic vs. gene therapy: IP is tightening around scaffold geometry and cell composition; FTO analysis required before committing to PLGA formulations (NIH CN 2024).
• Electrical (photovoltaic) vs. optogenetic (RGC-targeted gene therapy) approaches — Science has both; see science-corp.
• Nanomaterial subretinal prostheses (tellurium nanowires, photoacoustic films) remain pre-clinical: TeNWN receptive fields are smaller than normal RGCs (135.57 vs 163.02 deg² in mice) and stability is demonstrated only to 112 days (macaque) — can they close the resolution gap with photodiode arrays, and does broadband/NIR-II sensitivity carry clinical value (low-light use, infrared augmentation) beyond research novelty?
• Reimbursement and device longevity will decide commercial viability after CE mark; the Argus II episode makes participant-support obligations during company failure a live regulatory question (see implantable-bci-ethics).
• Post-implant monitoring IP thicket (Notal Vision, Roche, Novartis, EPFL) — any prosthetic device needing follow-up OCT monitoring may need to license or design around these filings.

Related pages

• intellimicro-medical — Chinese IMIE 256 epiretinal prosthesis (clinical)

• nanochap — Chinese 320-ch retinal visual BCI (clinical, GCP trial)

• iridium-medical — Taiwanese HARP4k subretinal prosthesis (preclinical)

• brain-computer-interface — category hub

• visual-prosthesis — combined retina + cortex umbrella

• cortical-visual-prosthesis — cortex sibling (Blindsight, Orion, Phosphoenix, Gennaris)

• retinal-prosthesis-companies — full company schema

• science-corp, pixium-vision, max-hodak — company/people pages

• brain-interface — cortical sibling (Blindsight, Orion, Gennaris)

• augmented-vision — DMD-based patterned-stimulation technology (the projection toolbox shared by light-driven prosthetics and AR displays)

References

• Holz FG, Le Mer Y, Muqit MMK, et al. Vision Restoration with the PRIMA System in Geographic Atrophy Due to AMD. N Engl J Med. 2026;394:232–242. DOI: 10.1056/NEJMoa2501396. PMID: 41124203. PMC7618305 (open access at https://pmc.ncbi.nlm.nih.gov/articles/PMC7618305/).
• Duncan J. NEJM 2026;394:298-301 (editorial). DOI: 10.1056/NEJMe2514592.
• Science Corp. press releases (2024–2026); BrightFocus Foundation (2026).
• “Restoration of Sight with Electronic Retinal Prostheses” (PMC12994432, 2025).
• PatSnap Eureka (2026). “Retinal Prosthesis Technology Landscape 2026.” AI-generated patent landscape analysis. https://www.patsnap.com/resources/blog/articles/retinal-prosthesis-patent-landscape-2026/ ¹⁹
• Leong A, Li Y, Ruikes TR, et al. A flexible photoacoustic retinal prosthesis. Nat Commun 17, 815 (2026). https://doi.org/10.1038/s41467-025-67518-6 ¹³
• Thurston A. “Could a Retinal Prosthesis Restore Sight for People with Age-Related Macular Degeneration?” The Brink, BU. 14 April 2026. https://www.bu.edu/articles/2026/retinal-prosthesis-age-related-macular-degeneration/ ¹⁴
• Strickland E, Harris M. “Their Bionic Eyes Are Now Obsolete and Unsupported.” IEEE Spectrum, 15 Feb 2022. https://spectrum.ieee.org/bionic-eye-obsolete ¹⁰
• Spherical Insights & Consulting. “Top 20 Companies in Global Artificial Retinal Implants Market (2026–2035): Expert View by Spherical Insights.” Aug 2026. https://www.sphericalinsights.com/blogs/top-20-companies-in-global-artificial-retinal-implants-market-2026-2035-expert-view-by-spherical-insights ¹²
• Wang S, Jiang C, Yu Y, et al. Tellurium nanowire retinal nanoprosthesis improves vision in models of blindness. Science 388(6751): eadu2987, 5 June 2025. DOI: 10.1126/science.adu2987. PMID: 40472078. ^{15 17}
• Fernández E. Nanowires replace lost retinal cells. Science 388(6751): 1025–1026, 5 June 2025. DOI: 10.1126/science.ady4439. PMID: 40472112. ¹⁸
• Zhang S, Rong Z, Chu L. Beyond vision restoration: broadband retinal nanoprosthetics with tellurium nanowire networks. Research (Wash DC) 8: 0857, 9 September 2025. DOI: 10.34133/research.0857. PMCID: PMC12417632 (CC BY 4.0). ¹⁶
• Palanker Lab (Stanford). Photovoltaic Retinal Prosthesis for Restoration of Sight in Retinal Degeneration (system design page). ²⁰
• Palanker D, Le Mer Y, Mohand-Said S, et al. Simultaneous perception of prosthetic and natural vision in AMD patients. Nat Commun 2022;13:513. DOI: 10.1038/s41467-022-28125-x ⁷
• Muqit MMK, Le Mer Y, Olmos de Koo L, et al. Prosthetic visual acuity with the PRIMA system at 4 years follow-up. Ophthalmol Sci 2024. ⁸
• Wang B-Y, Chen ZC, Bhuckory M, et al. Electronic photoreceptors enable prosthetic visual acuity matching the natural resolution in rats. Nat Commun 2022;13:6627. ⁶
• Mathieson K, Loudin J, Goetz G, et al. Photovoltaic retinal prosthesis with high pixel density. Nat Photonics 2012;6:391–397. ⁵
• PRIMA projector/chip patents: US12061332B2, US12201827B2, US10980997B2 (Pixium→Science Corp) — see visual-prosthesis-patents.
• Arens-Arad T, Farah N, Ben-Yaish S, Zlotnik A, Zalevsky Z, Mandel Y. Head mounted DMD based projection system for natural and prosthetic visual stimulation in freely moving rats. Sci Rep 6: 34873, 12 October 2016. DOI: 10.1038/srep34873. ³

Footnotes

1. raw/articles/science-corp-pixium-acquisition-2024.md ↩

2. raw/articles/brightfocus-prima-2026.md ↩

3. raw/papers/arens-arad-2016-dmd-head-mounted-projection.md ↩ ↩²

4. raw/articles/science-corp-prima-nejm-2025.md ↩

5. raw/papers/mathieson-2012-photovoltaic-retinal-prosthesis.md ↩ ↩²

6. raw/papers/wang-2022-electronic-photoreceptors-rats.md ↩ ↩²

7. raw/papers/palanker-2022-simultaneous-prosthetic-natural-vision.md ↩ ↩²

8. raw/papers/muqit-2024-prima-4-year-followup.md ↩ ↩²

9. raw/papers/holz-2026-prima-subretinal-photovoltaic.md ↩

10. raw/articles/ieee-spectrum-argus-obsolete-2022.md ↩ ↩²

11. raw/papers/retinal-prosthesis-review-2025.md ↩

12. raw/articles/sphericalinsights-artificial-retinal-implants-market-2026.md ↩ ↩²

13. raw/papers/leong-2026-photoacoustic-retinal-prosthesis.md ↩ ↩²

14. raw/articles/bu-photoacoustic-retinal-prosthesis-2026.md ↩ ↩²

15. raw/papers/wang-2025-tellurium-nanowire-retinal-nanoprosthesis.md ↩ ↩²

16. raw/papers/zhang-2025-beyond-vision-restoration-commentary.md ↩ ↩² ↩³

17. raw/papers/wang-2025-dmd-platform-excerpt.md ↩ ↩²

18. raw/papers/fernandez-2025-nanowires-replace-lost-retinal-cells.md ↩ ↩²

19. raw/articles/patsnap-retinal-prosthesis-patent-landscape-2026.md ↩ ↩² ↩³

20. raw/articles/palanker-lab-prima-system-2026.md ↩